TScan Therapeutics Announces Upcoming Virtual Investor Event
November 07, 2022 07:00 ET
|
TScan Therapeutics, Inc.
Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors Monday, November 14th at 5:00 PM ET WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc....
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
November 03, 2022 09:34 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
October 05, 2022 08:33 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T...
TScan Therapeutics to Participate in Upcoming Investor Conferences
September 22, 2022 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
September 12, 2022 07:00 ET
|
TScan Therapeutics, Inc.
Financing supports management’s focus on clinical execution and advancing its ImmunoBank Initial $30 million tranche extends cash runway into the second quarter of 2024 WALTHAM, Mass., Sept. 12,...
TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 07, 2022 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
August 10, 2022 07:00 ET
|
TScan Therapeutics, Inc.
Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs ...
TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
August 03, 2022 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T...
TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology
July 11, 2022 07:00 ET
|
TScan Therapeutics, Inc.
TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to neoadjuvant immunotherapy TCR for...
TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer
July 07, 2022 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...